Skip to content
Search

Latest Stories

Glenmark Life Sciences is now Alivus Life Sciences

Glenmark Life Sciences is now Alivus Life Sciences
Glenmark Life Sciences is now Alivus Life Sciences

Nirma acquired a majority stake in Glenmark Life Sciences in March 2024, becoming the new promoter of the company 

Indian pharmaceutical company Glenmark Life Sciences (GLS) has rebranded as Alivus Life Sciences, following its acquisition by consumer goods holding conglomerate Nirma Limited.

It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes.


In March 2024, Nirma Limited, headquartered in Ahmedabad, India, acquired a 75 per cent majority stake in Glenmark Life Sciences, becoming the new promoter of the company.

The pharmaceutical company has described the rebranding to Alivus Life Sciences as “an exciting new chapter” in its journey.

In a press release, the company explained: “The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and contract development and manufacturing organization (CDMO) space.

“The new identity, Alivus Life Sciences, represents vitality and growth with a renewed focus. It embodies the optimism and transformation the company is embracing as it enters the next phase of its journey.”

Along with the name change, the company’s official website is now alivus.com.

For the first half of FY25, Glenmark Life Sciences reported revenue from operations of Rs. 10,955 million (around £120 million), a 6.7 per cent year-on-year decrease. In Q2FY25, revenue from operations was reported at Rs. 5,069 million (approximately £53.22 million)

Dr. Yasir Rawjee, MD and CEO of Glenmark Life Sciences attributed the revenue decline to the temporary closure of the Ankleshwar facility, which delayed order fulfillment across geographies.

However, the loss of production has substantially been recovered and the company expects the second half of FY25 to outperform their earlier estimates.

Dr. Rawjee also highlighted that the company's product mix has led to improved gross margins of over 55 per cent.

“Looking ahead, we expect a strong second half of the fiscal year, supported by our solid order book. While overall growth for FY25 is projected to be in high single digits, we are confident in maintaining stable margins throughout the year,” he added.

Alivus Life Sciences provides CDMO services to a range of multinational and specialty pharmaceutical companies and has a portfolio of 161 molecules. The company supplies its products across India, Europe, North America, Latin America, Japan, and the rest of the world.

The company operates four manufacturing facilities, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe).

More For You

NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Free morning-after pill at pharmacies to end postcode lottery for patients

Pharmacy technicians will be allowed to supply of drospirenone for contraception under PGD,

gettyimages

Pharmacy contract: Free morning-after pill to be available at pharmacies soon

The UK government has announced that, for the first time ever, the ‘morning-after pill’ or emergency contraceptive pill will be available free of charge at pharmacies on the NHS, ending the postcode lottery women face in accessing the medicine and reducing inequalities.

The Department of Health and Social Care (DHSC) has confirmed a record £3.073 billion funding package for community pharmacies in 2025/26, alongside an additional £215 million to sustain Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Royal College status: The PDA calls for ‘meaningful and collaborative dialogue’

The profession’s success will depend on collaboration across all sectors, says PDA.

gettyimages

Royal College vote: Less than 7% of GB pharmacists in favour, says PDA

The Pharmacists’ Defence Association (PDA) has criticised the Royal Pharmaceutical Society (RPS) for moving too quickly to a ballot on its proposed transition to a Royal College, arguing that it resulted in low participation from pharmacists in Great Britain.

Announcing the results of the special resolution vote, the RPS said that the outcome was a “clear mandate” in favour of the transformative change.

Keep ReadingShow less
RPS Wales calls for urgent investment in pharmacy workforce at Senedd meeting

Third from the left: Eluned Morgan, First Minister of Wales

Photo credit: RPS

Invest in pharmacy workforce: RPS Wales urges Senedd members

Members of the Senedd (MSs) were briefed on the increasing pressures facing pharmacy teams and the urgent need for action to support their health and wellbeing at an event hosted by the Royal Pharmaceutical Society (RPS) Wales.

The event, held on Wednesday, brought together MSs, including first minister Eluned Morgan, to discuss the findings of RPS’ latest Workforce Wellbeing Survey.

Keep ReadingShow less
Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less